Catheters and Tools with Pulsed Field Ablation—Pulmonary Vein Isolation and Nanosecond Pulse Field Ablation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F25%3A00010045" target="_blank" >RIV/00023884:_____/25:00010045 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10511095
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S1877918225000176?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S1877918225000176?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ccep.2025.02.015" target="_blank" >10.1016/j.ccep.2025.02.015</a>
Alternative languages
Result language
angličtina
Original language name
Catheters and Tools with Pulsed Field Ablation—Pulmonary Vein Isolation and Nanosecond Pulse Field Ablation
Original language description
Pulse Field Ablation (PFA) has gained attention in the field of atrial fibrillation catheter treatment recently and the initial PFA systems have demonstrated excellent safety and efficacy profiles. All currently used or developed technologies use ultrashort pulses (on the order of microseconds) to create strong electrical field for myocardial tissue ablation. The Emerging CellFX System (Pulse Biosciences, Inc.) utilizes nanosecond PFA (nsPFA), whose pulses last less than a microsecond, typically tens to hundreds of nanoseconds, and are thus several orders of magnitude shorter than the initial PFA systems. There are several potential advantages of nsPFA over microsecond PFA such as deeper penetration of the electric field into tissue, creating larger and deeper ablation zones while depositing less overall energy and heat, faster treatment and less muscle stimulation or nerve capture. The safety and effectivity of nsPFA in cardiac tissue has already been demonstrated in an animal model. Since December 2023, the first in man feasibility clinical trial using nsPFA has been taking place at Na Homolce Hospital in Prague, Czech Republic. 54 patients with paroxysmal atrial fibrillation have already been included in the study. Preliminary experience with CellFX technology performance is encouraging and final results are expected during 2025.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cardiac Electrophysiology Clinics
ISSN
1877-9182
e-ISSN
—
Volume of the periodical
17
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
273-285
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-105000274411